Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26073193 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Przemyslaw Zygmunciak und 6 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland. Hauptthemen laut MEDLINE: Leukemia, Lymphocytic, Chronic, B-Cell, Agammaglobulinaemia Tyrosine Kinase, Proto-Oncogene Proteins c-bcl-2, Protein Kinase Inhibitors. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 108 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
In the recent 2024 ESMO guidelines, the combination of venetoclax and ibrutinib was listed as one of the first-line treatment options for CLL patients. These drugs were first-in-class medicines that revolutionized CLL management, extending patients’ overall survival even in cases refractory to immunochemotherapy. However, since the approval of both compounds, more and more Bruton Tyrosine Kinase inhibitors (BTKis) and B-cell lymphoma 2 inhibitors (BCL2is) have been discovered. Their efficacy and safety are the reasons for their use in monotherapy among both treatment-naïve and relapsed patients with CLL. Currently, several ongoing clinical trials are investigating the rationale for the combination of BCL2is and BTKis. In this review, we discuss the recent advancements in the field of co-therapy with BTKis and BCL2is.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Faculty of Medicine, Warsaw Medical University, 02-091 Warsaw, Poland.
- Department of Hematology, Medical University of Lodz, 93-510 Lodz, Poland.
- Department of General Hematology, Copernicus Memorial Hospital, 93-510 Lodz, Poland.
ORCID-Profile: Przemyslaw Zygmunciak, Hanna Dancewicz, Olga Błażowska, Krzysztof Bieliński, Tadeusz Robak
Zitieren
APA
Zygmunciak, P., Dancewicz, H., Stróżna, K., Błażowska, O., Bieliński, K., Robak, T., & Puła, B. (2025). Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26073193
Vancouver
Zygmunciak P, Dancewicz H, Stróżna K, Błażowska O, Bieliński K, Robak T, et al. Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26073193
BibTeX
@article{Zygmunciak2025,
author = {Zygmunciak, Przemyslaw and Dancewicz, Hanna and Stróżna, Katarzyna and Błażowska, Olga and Bieliński, Krzysztof and Robak, Tadeusz and Puła, Bartosz},
title = {Double Strike in Chronic Lymphocytic Leukemia—The Combination of BTK and BCL2 Inhibitors in Actual and Future Clinical Practice},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26073193}
}
EUVIMED